{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:47:17Z","timestamp":1777466837377,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.clinthera.2012.02.019","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T15:32:28Z","timestamp":1332862348000},"page":"915-925.e2","source":"Crossref","is-referenced-by-count":16,"title":["Economic Evaluation of Sequential Treatments for Follicular Non-Hodgkin Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Erkki J.","family":"Soini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne A.","family":"Martikainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ville","family":"Vihervaara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Mustonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapio","family":"Nousiainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.02.019_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/2040620711407675","article-title":"Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation","volume":"2","author":"Walker","year":"2011","journal-title":"Ther Adv Hemat"},{"key":"10.1016\/j.clinthera.2012.02.019_bib2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.3109\/10428194.2011.592623","article-title":"Economic impact of disease progression in follicular non-Hodgkin lymphoma","volume":"52","author":"Beveridge","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2012.02.019_bib3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/11314820-000000000-00000","article-title":"Economic burden of follicular non-Hodgkin's lymphoma","volume":"27","author":"Foster","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2012.02.019_bib4","doi-asserted-by":"crossref","first-page":"vi59","DOI":"10.1093\/annonc\/mdr388","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Dreyling","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2012.02.019_bib5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/annonc\/mdq582","article-title":"Treatment of follicular non-Hodgkin lymphoma with or without rituximab: cost-effectiveness and value of information based on 5-year follow-up","volume":"22","author":"Soini","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2012.02.019_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","article-title":"Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation","volume":"28","author":"Deconinck","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2012.02.019_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3310\/hta13suppl2\/06","article-title":"Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma","volume":"13","author":"Boland","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.clinthera.2012.02.019_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10428190701769665","article-title":"Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma","volume":"49","author":"Hornberger","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2012.02.019_bib9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/02841860802120028","article-title":"Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden","volume":"47","author":"Kasteng","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clinthera.2012.02.019_bib10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1524-4733.2009.00676.x","article-title":"An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK","volume":"13","author":"Ray","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2012.02.019_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.02.019_bib12","series-title":"Abstract presented at: 51st American Society of Hematology Annual Meeting and Exposition; December 5\u20138","author":"Rummel","year":"2009"},{"key":"10.1016\/j.clinthera.2012.02.019_bib13","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.02.019_bib14","first-page":"1729","article-title":"Follicular lymphoma [in Finnish]","volume":"62","author":"Jyrkki\u00f6","year":"2007","journal-title":"Finnish Med J"},{"key":"10.1016\/j.clinthera.2012.02.019_bib15","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.02.019_bib16","series-title":"Deaths during year 2009 [in Finnish]","year":"2010"},{"key":"10.1016\/j.clinthera.2012.02.019_bib17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdm543","article-title":"The impact of follicular lymphoma on health-related quality of life","volume":"19","author":"Pettengell","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2012.02.019_bib18","series-title":"Finnish Medicine Tariff [in Finnish]","year":"2011"},{"key":"10.1016\/j.clinthera.2012.02.019_bib19","series-title":"Health care unit costs in Finland in year 2008 [in Finnish]","author":"Hujanen","year":"2008"},{"key":"10.1016\/j.clinthera.2012.02.019_bib20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1524-4733.2008.00358.x","article-title":"Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI)","volume":"11","author":"Barton","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2012.02.019_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Statistical Science"},{"key":"10.1016\/j.clinthera.2012.02.019_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/annonc\/mdf119","article-title":"Survival after progression in patients with follicular lymphoma: analysis of prognostic factors","volume":"13","author":"Montoto","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2012.02.019_bib23","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.1992.10.6.942","article-title":"Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation","volume":"10","author":"Weisdorf","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.02.019_bib24","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.02.019_bib25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Res Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.02.019_bib26","doi-asserted-by":"crossref","first-page":"A470","DOI":"10.1016\/j.jval.2011.08.1296","article-title":"Health related quality of life of long term survivors of lymphoma: a population based study","volume":"14","author":"Blommestein","year":"2011","journal-title":"Value Health"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T22:26:14Z","timestamp":1543098374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0149291812000987"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.02.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}